102.365 USD
+0.1 (+0.1%)
Taking everything into account, EXAS scores 4 out of 10 in our fundamental rating. EXAS was compared to 528 industry peers in the Biotechnology industry. While EXAS seems to be doing ok healthwise, there are quite some concerns on its profitability. EXAS has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- In the past year EXAS has reported negative net income.
- EXAS had a positive operating cash flow in the past year.
- EXAS had negative earnings in each of the past 5 years.
- The reported operating cash flow has been mixed in the past 5 years: EXAS reported negative operating cash flow in multiple years.
1.2 Ratios
- EXAS has a better Return On Assets (-16.72%) than 78.41% of its industry peers.
- EXAS has a better Return On Equity (-39.44%) than 71.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROIC | N/A |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- EXAS has a Gross Margin of 67.37%. This is amongst the best in the industry. EXAS outperforms 80.49% of its industry peers.
- In the last couple of years the Gross Margin of EXAS has declined.
- EXAS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
2. Health
2.1 Basic Checks
- EXAS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for EXAS has been increased compared to 1 year ago.
- EXAS has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, EXAS has a worse debt to assets ratio.
2.2 Solvency
- EXAS has an Altman-Z score of 2.97. This is not the best score and indicates that EXAS is in the grey zone with still only limited risk for bankruptcy at the moment.
- EXAS's Altman-Z score of 2.97 is fine compared to the rest of the industry. EXAS outperforms 68.18% of its industry peers.
- The Debt to FCF ratio of EXAS is 9.47, which is on the high side as it means it would take EXAS, 9.47 years of fcf income to pay off all of its debts.
- EXAS has a Debt to FCF ratio of 9.47. This is amongst the best in the industry. EXAS outperforms 90.91% of its industry peers.
- EXAS has a Debt/Equity ratio of 0.93. This is a neutral value indicating EXAS is somewhat dependend on debt financing.
- EXAS has a worse Debt to Equity ratio (0.93) than 74.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 2.97 |
ROIC/WACCN/A
WACC8.13%
2.3 Liquidity
- EXAS has a Current Ratio of 2.72. This indicates that EXAS is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.72, EXAS is doing worse than 67.99% of the companies in the same industry.
- A Quick Ratio of 2.44 indicates that EXAS has no problem at all paying its short term obligations.
- With a Quick ratio value of 2.44, EXAS is not doing good in the industry: 69.13% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 |
3. Growth
3.1 Past
- EXAS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -354.70%.
- EXAS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 14.47%.
- The Revenue has been growing by 25.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
3.2 Future
- Based on estimates for the next years, EXAS will show a very strong growth in Earnings Per Share. The EPS will grow by 21.50% on average per year.
- EXAS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.01% yearly.
EPS Next Y87.09%
EPS Next 2Y43.47%
EPS Next 3Y30.54%
EPS Next 5Y21.5%
Revenue Next Year17.56%
Revenue Next 2Y15.52%
Revenue Next 3Y14.5%
Revenue Next 5Y11.01%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- EXAS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- With a Price/Forward Earnings ratio of 314.71, EXAS can be considered very expensive at the moment.
- Based on the Price/Forward Earnings ratio, EXAS is valued cheaply inside the industry as 87.69% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of EXAS to the average of the S&P500 Index (24.12), we can say EXAS is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 314.71 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, EXAS is valued cheaply inside the industry as 88.83% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of EXAS indicates a rather cheap valuation: EXAS is cheaper than 92.42% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 78.62 | ||
| EV/EBITDA | 324.42 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- EXAS's earnings are expected to grow with 30.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.47%
EPS Next 3Y30.54%
5. Dividend
5.1 Amount
- EXAS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:EXAS (1/15/2026, 3:13:09 PM)
102.365
+0.1 (+0.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-17 2026-02-17/amc
Inst Owners94.41%
Inst Owner Change0.5%
Ins Owners0.85%
Ins Owner Change-0.21%
Market Cap19.43B
Revenue(TTM)3.08B
Net Income(TTM)-986.58M
Analysts68.28
Price Target100.65 (-1.68%)
Short Float %2.76%
Short Ratio0.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.24%
Min EPS beat(2)-40.06%
Max EPS beat(2)94.53%
EPS beat(4)1
Avg EPS beat(4)-344.13%
Min EPS beat(4)-1391.93%
Max EPS beat(4)94.53%
EPS beat(8)4
Avg EPS beat(8)-160.89%
EPS beat(12)8
Avg EPS beat(12)-92.72%
EPS beat(16)11
Avg EPS beat(16)-67.39%
Revenue beat(2)2
Avg Revenue beat(2)2.8%
Min Revenue beat(2)2.65%
Max Revenue beat(2)2.95%
Revenue beat(4)3
Avg Revenue beat(4)1.49%
Min Revenue beat(4)-0.27%
Max Revenue beat(4)2.95%
Revenue beat(8)3
Avg Revenue beat(8)0.13%
Revenue beat(12)6
Avg Revenue beat(12)1.15%
Revenue beat(16)10
Avg Revenue beat(16)1.59%
PT rev (1m)0%
PT rev (3m)51.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1962.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 314.71 | ||
| P/S | 6.3 | ||
| P/FCF | 78.62 | ||
| P/OCF | 50.22 | ||
| P/B | 7.77 | ||
| P/tB | N/A | ||
| EV/EBITDA | 324.42 |
EPS(TTM)-5.32
EYN/A
EPS(NY)0.33
Fwd EY0.32%
FCF(TTM)1.3
FCFY1.27%
OCF(TTM)2.04
OCFY1.99%
SpS16.24
BVpS13.18
TBVpS-4.26
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -16.72% | ||
| ROE | -39.44% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 67.37% | ||
| FCFM | 8.02% |
ROA(3y)-10.17%
ROA(5y)-11.23%
ROE(3y)-23.27%
ROE(5y)-24.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.06%
GM growth 5Y-1.57%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.93 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | 36.88 | ||
| Cap/Depr | 63.99% | ||
| Cap/Sales | 4.53% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 611.3% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.44 | ||
| Altman-Z | 2.97 |
F-Score4
WACC8.13%
ROIC/WACCN/A
Cap/Depr(3y)84.38%
Cap/Depr(5y)130.41%
Cap/Sales(3y)7.28%
Cap/Sales(5y)12.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-354.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y87.09%
EPS Next 2Y43.47%
EPS Next 3Y30.54%
EPS Next 5Y21.5%
Revenue 1Y (TTM)14.47%
Revenue growth 3Y16.01%
Revenue growth 5Y25.78%
Sales Q2Q%20.05%
Revenue Next Year17.56%
Revenue Next 2Y15.52%
Revenue Next 3Y14.5%
Revenue Next 5Y11.01%
EBIT growth 1Y25.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year328.5%
EBIT Next 3Y83.49%
EBIT Next 5Y52.7%
FCF growth 1Y1146.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y179.09%
OCF growth 3YN/A
OCF growth 5YN/A
EXACT SCIENCES CORP / EXAS FAQ
What is the fundamental rating for EXAS stock?
ChartMill assigns a fundamental rating of 4 / 10 to EXAS.
What is the valuation status of EXACT SCIENCES CORP (EXAS) stock?
ChartMill assigns a valuation rating of 4 / 10 to EXACT SCIENCES CORP (EXAS). This can be considered as Fairly Valued.
How profitable is EXACT SCIENCES CORP (EXAS) stock?
EXACT SCIENCES CORP (EXAS) has a profitability rating of 2 / 10.
What is the earnings growth outlook for EXACT SCIENCES CORP?
The Earnings per Share (EPS) of EXACT SCIENCES CORP (EXAS) is expected to grow by 87.09% in the next year.